je.st
news
Tag: therapeutics
New Study: Sevion Therapeutics, Inc. (SVON) - Financial and Strategic SWOT Analysis Review
2015-06-21 19:47:05| Agriculture - Topix.net
The company provides eukaryotic translation initiation Factor 5A technology to regulate cell death and survival. It offers products and technologies in the areas of eIF5A, cancer, and inflammation.
Tags: review
study
analysis
financial
United Therapeutics faces patent attack on major drug
2015-06-17 10:51:55| Biotech - Topix.net
United Therapeutics Corporation is facing a possible patent fight over a drug that brings in one-third of the company's total revenue. Watson Laboratories, Inc. submitted an Abbreviated New Drug Application with the U.S. Food and Drug Administration requesting approval to market a generic version of Tyvaso, a drug for which United claims it has patent protection.
Tags: united
major
drug
attack
Aimmune Therapeutics Announces Positive Phase 2 Study Results Of AR101 For The Treatment Of Peanut Allergy
2015-06-17 06:39:17| foodingredientsonline Home Page
Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced recently that a Phase 2 study (ARC001) evaluating the company’s lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively
Tags: of
results
study
positive
Nivalis Therapeutics A No-Brainer For Biotech Investors
2015-06-15 22:09:24| Biotech - Topix.net
Nivalis Therapeutics is a mid-clinical trial stage pharmaceutical company working with therapies that target certain gene mutations in cystic fibrosis patients. The company is preparing for its initial public offering to raise funds for continuing clinical trials and research.
Tags: investors
biotech
therapeutics
nobrainer
Abbvie 'Enhanzes' Halozyme Therapeutics coffers in potential $1.193B collaboration
2015-06-04 06:37:32| Logistics - Topix.net
Fresh off reporting good news at the American Society of Clinical Oncology annual meeting in Chicago, Halozyme Therapeutics Inc. segued into yet another global collaboration and license agreement - this time with Abbvie Inc. - that could add $1.193 billion to its coffers. The deal allows Abbvie, of North Chicago, to apply Halozyme's Enhanze delivery platform to up to nine of its compounds in return for $23 million up front to Halozyme and milestone payments totaling approximately $130 million for each collaboration target.
Tags: potential
collaboration
therapeutics
coffers
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] next »